IP Library Granted Patent US 11,266,698
Granted Patent B2
US 11,266,698 · App. 15/906,988 · Granted Mar 8, 2022

Bacterium for use as a probiotic for nutritional and medical applications

Inventors: Denise Kelly (Aberdeen, GB); Imke Mulder (Aberdeen, GB)
Assignee: 4D Pharma Research Limited
A61K35/741A23K10/18A23L33/135A61K9/0053A61K35/74A61K45/06C12N1/20A23V2002/00A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,266,698
App. No.
15/906,988
Granted
Mar 8, 2022
Kind
B2
Abstract

A first aspect of the invention relates to the bacterial species Roseburia hominis for use in: regulating the immune system of a subject treating an immune disorder; treating an intestinal disorder; improving intestinal microbiota; regulating the innate immune system of a subject; regulating the adaptive immune system of a subject; regulating appetite in a subject; promoting Tregs and immune tolerance; promoting gut health in a subject; and/or maintaining immune homeostasis in a subject. Further aspects of the invention relate to compositions comprising Roseburia hominis.

Claims (13)

1. A composition that comprises a lyophilized Roseburia bacteria strain, wherein the Roseburia bacteria strain is the Roseburia hominis strain deposited under accession number NCIMB 14029, wherein the composition comprises from about 1×10 6 to about 1×10 11 colony forming units of the bacteria strain per gram (CFU/g) with respect to a weight of the composition; and an excipient, carrier or diluent, wherein the composition is a solid unit dose tablet or capsule formulation, and wherein the capsule is formulated for delivery of the Roseburia bacteria strain to a colon or an ileum when administered orally to a subject.

2. The composition of claim 1 , wherein the composition produces a decrease in at least one pro-inflammatory cytokine when administered orally to the subject, wherein the decrease is in comparison to a corresponding subject not administered with the composition.

3. The composition of claim 1 , wherein the composition comprises a carrier, wherein the carrier is selected from the group consisting of lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and combinations thereof.

4. The composition of claim 1 , wherein the composition is an edible composition.

5. The composition of claim 1 , wherein the composition is a probiotic composition.

6. The composition of claim 1 , wherein the composition further comprises a prebiotic compound.

7. The composition of claim 6 , wherein the prebiotic compound is a carbohydrate, inulin or a transgalacto-oligosaccharide.

8. The composition of claim 7 , wherein the composition comprises the carbohydrate, and wherein the carbohydrate is selected from the group consisting of: fructo-oligosaccharides; short-chain fructo-oligosaccharides; isomalt-oligosaccharides; pectins; xylooligosaccharides; chitosan-oligosaccharides; beta-glucans; arable gum modified and resistant starches; polydextrose; D-tagatose; acacia fibers; carob; oats; and citrus fibers.

9. The composition of claim 6 , wherein the prebiotic compound is in an amount of from about 1% to about 20% by weight with respect to a total weight of the composition.

10. The composition of claim 1 , wherein the composition further comprises at least one additional bacterium.

11. The composition of claim 10 , wherein the at least one additional bacterium is a food grade bacterium.

12. The composition of claim 11 , wherein the food grade bacterium is selected from the group consisting of lactic acid bacteria, bifidobacteria, propionibacteria, and mixtures thereof.

13. The composition of claim 1 , further comprising an oxygen scavenger.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED
To: CJ BIOSCIENCE, INC.
Reel/Frame 063992/0427 →
CHANGE OF NAME Recorded May 8, 2019
From: GT BIOLOGICS LIMITED
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 049117/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: MULDER, IMKE
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 049122/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: KELLY, DENISE
To: GT BIOLOGICS LIMITED
Reel/Frame 049122/0054 →
Priority Claims (1)
GB 1117313 · Oct 7, 2011 · national
Continuity (3)
Division 15070605 · Mar 15, 2016
Continuation 14349907
Related Publication 20180271918A1 · Sep 27, 2018